APOBEC shapes tumor evolution and age at onset of lung cancer in smokers

Tongwu Zhang,Jian Sang,Phuc H. Hoang,Wei Zhao,Jennifer Rosenbaum,Kofi Ennu Johnson,Leszek J. Klimczak,John McElderry,Alyssa Klein,Christopher Wirth,Erik N. Bergstrom,Marcos Díaz-Gay,Raviteja Vangara,Frank Colon-Matos,Amy Hutchinson,Scott M. Lawrence,Nathan Cole,Bin Zhu,Teresa M. Przytycka,Jianxin Shi,Neil E. Caporaso,Robert Homer,Angela C. Pesatori,Dario Consonni,Marcin Imielinski,Stephen J. Chanock,David C. Wedge,Dmitry A. Gordenin,Ludmil B. Alexandrov,Reuben S. Harris,Maria Teresa Landi

DOI: https://doi.org/10.1101/2024.04.02.587805

2024-04-03

Abstract:APOBEC enzymes are part of the innate immunity and are responsible for restricting viruses and retroelements by deaminating cytosine residues . Most solid tumors harbor different levels of somatic mutations attributed to the off-target activities of APOBEC3A (A3A) and/or APOBEC3B (A3B) . However, how APOBEC3A/B enzymes shape the tumor evolution in the presence of exogenous mutagenic processes is largely unknown. Here, by combining deep whole-genome sequencing with multi-omics profiling of 309 lung cancers from smokers with detailed tobacco smoking information, we identify two subtypes defined by low ( ) and high ( ) APOBEC mutagenesis. LAS are enriched for A3B-like mutagenesis and mutations, whereas HAS for A3A-like mutagenesis and mutations. Unlike , expression is strongly associated with an upregulation of the base excision repair pathway. Hypermutation by unrepaired A3A and tobacco smoking mutagenesis combined with -induced genomic instability can trigger senescence , apoptosis , and cell regeneration , as indicated by high expression of pulmonary healing signaling pathway, stemness markers and distal cell-of-origin in HAS. The expected association of tobacco smoking variables (e.g., time to first cigarette) with genomic/epigenomic changes are not observed in HAS, a plausible consequence of frequent cell senescence or apoptosis. HAS have more neoantigens, slower clonal expansion, and older age at onset compared to LAS, particularly in heavy smokers, consistent with high proportions of newly generated, unmutated cells and frequent immuno-editing. These findings show how heterogeneity in mutational burden across co-occurring mutational processes and cell types contributes to tumor development, with important clinical implications.

Genomics